Pfizer Starts Stem Cell R&D Unit

Xconomy Boston — 

Drug giant Pfizer (NYSE:PFE) has announced the launch of Pfizer Regenerative Medicine, an independent research unit focused on discovering stem cell treatments for multiple diseases. New York-based Pfizer says the research unit will be co-located in Cambridge, U.K., and at its existing R&D operation— Research Technology Centre—in Cambridge, MA.